Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28345846 | 0.81 | TSHR (0.50) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL2021969 | 0.81 | CYP1A2 (0.46) | TSHRKMT2AKDM4EMAPK1L3MBTL1 | |
| SCHEMBL6990252 | 0.77 | TSHR (0.44) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL2407523 | 0.77 | KDM5B (0.34) | TSHRKMT2AKDM4EL3MBTL1CYP1A2 | |
| SCHEMBL2411055 | 0.75 | TSHR (0.48) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL2405581 | 0.75 | TSHR (0.48) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL2407562 | 0.74 | GLP1R (0.51) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL6990393 | 0.74 | TSHR (0.44) | TSHRGLP1RKMT2AKDM4EMAPK1 | |
| SCHEMBL2019925 | 0.73 | TSHR (0.63) | TSHRGLP1RKMT2AKDM4EL3MBTL1 | |
| SCHEMBL2025570 | 0.73 | TSHR (0.63) | TSHRGLP1RKMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | TSHR 2981/4885GLP1R 130/4885KMT2A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.